Home / Therapies / GLP-1 Agonist Therapy Center (page 5)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

GLP-1/GIP Drug Shows Promise in Reducing A1c and Reducing Weight

Nov 10, 2018 Articles, GLP-1 Agonist Therapy Center

New combination drug has better efficacy in glucose control and weight loss than when taken separately.

Oral Semaglutide Shows Promise in HbA1c Reduction and Weight Loss

Nov 3, 2018 Articles, GLP-1 Agonist Therapy Center, Obesity, Type 2 Diabetes

First oral GLP-1 agonist undergoing Phase 3 trials shows significant benefits managing type 2 diabetes.

Albiglutide’s Effect on Cardiovascular Outcomes in People with Type 2 Diabetes

Nov 3, 2018 Articles, Cardiology, GLP-1 Agonist Therapy Center, Type 2 Diabetes

Study looks at convenient once-weekly GLP-1 that can reduce chances of heart attacks and strokes.

GLP-1 Agonist Medications Chart

Nov 1, 2018 GLP-1 Agonist Therapy Center, Tools

This GLP-1 Agonist Medications Chart outlines the latest GLP-1 medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike. The chart is in PDF format. Use this link to download: GLP-1 Agonist Medications Chart

Comparison of Semaglutide versus Liraglutide for Weight Loss in Patients with Obesity

Oct 20, 2018 Articles, GLP-1 Agonist Therapy Center, Obesity

Researchers study efficacy and safety of GLP-1 inhibitors on weight loss.

Semaglutide May Foster Significant Weight Loss in Patients with Obesity

Oct 6, 2018 Articles, GLP-1 Agonist Therapy Center, Obesity

When combined with diet and exercise, GLP-1 medication showed significant weight loss compared to liraglutide and placebo, a new study finds.

GLP-1 Agonists Do Not Increase Risk for Diabetic Retinopathy

Oct 6, 2018 Articles, GLP-1 Agonist Therapy Center, Ophthalmology

New findings compare treatment with patients taking two or more glucose-lowering agents.

Liraglutide Lowers Risk for Amputation in Patients with Type 2 Diabetes and CV Risk

Sep 29, 2018 Articles, GLP-1 Agonist Therapy Center, Podiatry, Type 2 Diabetes

Investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.

Poster Summaries of Interest at the 78th ADA Scientific Sessions

Jul 14, 2018 Articles, Diet & Nutrition, GLP-1 Agonist Therapy Center, SGLT-2 Therapy Center, Type 1 Diabetes, Type 2 Diabetes

Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.

A Comparison of Safety and Efficacy of Semaglutide vs. Exenatide ER

Feb 10, 2018 Articles, GLP-1 Agonist Therapy Center

GLP-1 agonists randomized showdown. Which agent is better?

Page 5 of 18« First...«3 456 7 » 10...Last »